Geron Corp (NASDAQ: GERN)

Geron Corporation is a commercial stage biopharmaceutical company focused on changing the course of blood cancer. Its lead product RYTELO (imetelstat) is a first in class telomerase inhibitor that received FDA approval in June 2024 for adult patients with low to intermediate 1 risk myelodysplastic syndromes who have transfusion dependent anemia and have not responded to or are ineligible for erythropoiesis stimulating agents. The company also obtained European Commission approval in March 2025 for the same indication. Geron Corporation is advancing additional clinical programs to evaluate imetelstat in relapsed refractory myelofibrosis and other myeloid malignancies. The mechanism of action involves direct inhibition of the telomerase enzyme, which is overactive in malignant stem and progenitor cells, thereby limiting their proliferative capacity. Clinical data from the IMerge trial showed durable red blood cell transfusion independence and supported the drug’s potential disease modifying activity. These attributes position RYTELO as a novel therapeutic option in hematologic oncology.

The company generates revenue primarily from the sale of RYTELO in the United States following its commercial launch in June 2024. Sales are made to healthcare providers, hospitals and specialty clinics that administer the product to eligible patients. Additional revenue arises from limited access programs outside the United States through Named Patient Partnerships, which to date have contributed minimal amounts. Geron Corporation is preparing for a planned commercial launch in select European markets in 2026, which is expected to create a new revenue stream pending reimbursement and market access approvals. The company also pursues potential milestone payments and royalties from future collaborations, although no material license agreements are currently in place.

Geron Corporation holds a differentiated position in the hematologic oncology market as the sole approved telomerase inhibitor for myelodysplastic syndromes and is pursuing broader applications in myelofibrosis. Key competitors in lower risk MDS include erythropoiesis stimulating agents such as epoetin alfa and darbepoetin alfa, the agent luspatercept, and hypomethylating agents like azacitabine and decitabine. In relapsed refractory myelofibrosis the company faces competition from JAK inhibitors including ruxolitinib, fedratinib and momelotinib. Competitive advantages stem from its novel mechanism of action, clinical evidence of durable transfusion independence, potential disease modifying activity, strong payer access, orphan drug exclusivity and a growing patent portfolio extending into the 2030s. The drug has been incorporated into the National Comprehensive Cancer Network Guidelines as a preferred option in certain patient subgroups, reinforcing its clinical credibility. Furthermore, the orphan drug designation provides seven years of market exclusivity in the United States and ten years in the European Economic Area, limiting generic competition for a substantial period.

The company serves adult patients with low to intermediate 1 risk myelodysplastic syndromes who require red blood cell transfusions and are ineligible for erythropoiesis stimulating agents, as well as patients with relapsed refractory myelofibrosis who have progressed after JAK inhibitor therapy. These patient populations represent a significant unmet medical need, with estimates of tens of thousands of individuals in the United States alone. Customers also include hospitals, oncology clinics and specialized transfusion centers that administer the product and manage patient care. In addition, Geron Corporation works with health insurance providers, managed care organizations and government payers to secure coverage and reimbursement for RYTELO. The company’s patient support program, REACH4RYTELO, assists eligible individuals with access, affordability and education related to therapy.